Abhijeet Lokras

Mr. Abhijeet Lokras

University of Copenhagen, Faculty of Pharmaceutical Sciences, Department of Pharmaceutics and Analytical Chemistry
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Abishek WadhwaAbishek Wadhwa
Abishek Wadhwa
AAAnas Aljabbari
Anas Aljabbari
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
Camilla FogedCamilla Foged
Camilla Foged
Aneesh ThakurAneesh Thakur
Aneesh Thakur
In the past few years, there has been increasing focus on the use of messenger RNA (mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement therapies, and treatment of genetic diseases. However, challenges that impede the successful translation of these molecules into drugs are that (i) mRNA is a very large molecule, (ii) it is intrinsically unstable and prone to degradation by nucleases, and (iii) it activates the immune system. Although some of these challenges have been partially solved by means of chemical modification of the mRNA, intracellular delivery of mRNA still represents a major hurdle. The clinical translation of mRNA-based therapeutics requires delivery technologies that can ensure stabilization of mRNA under physiological conditions. Here, we (i) review opportunities and challenges in the delivery of mRNA-based therapeutics with a focus on non-viral delivery systems, (ii) present the clinical status of mRNA vaccines, and (iii) highlight perspectives on the future of this promising new type of medicine.

16 March 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
MOMelike Ongun
Melike Ongun
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
SBSaahil Baghel
Saahil Baghel
ZSZhenning Shi
Zhenning Shi
SSSigne Schmidt
Signe Schmidt
Camilla FogedCamilla Foged
Camilla Foged
Design of inhalable mRNA therapeutics is promising because local administration in the respiratory tract is minimally invasive and induces a local response. However, several challenges related to administration via inhalation and respiratory tract barriers have so far prevented the progress of inhaled mRNA therapeutics. Here, we investigated factors of importance for lipid nanoparticle (LNP)-mediated delivery of mRNA to the respiratory tract. We hypothesized that: (i) the PEG-lipid content is important for providing colloidal stability during aerosolization and for mucosal delivery, (ii) the PEG-lipid contentinfluences the expression of mRNA-encoded protein in the lungs, and (iii) the route of administration (nasal versus pulmonary) affects mRNA delivery in the lungs. In this study, we aimed to optimize the PEG-lipid content for mucosal delivery and to investigatethe effect of administration route on the kinetics of protein expression. Our results show that increasing the PEG-lipid content improves the colloidal stability during the aerosolization process, but has a negative impact on the transfection efficiencyin vitro. The kinetics of protein expressionin vivois dependent on the route of administration, and we found that pulmonaryadministration of mRNA-LNPs to mice results inmore durable protein expression than nasaladministration. These results demonstrate that the design of the delivery system and the route of administration are importantfor achieving high mRNA transfection efficiency in the respiratory tract.

2 August 2019 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
CDCypriane Dormenval
Cypriane Dormenval
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
GCGuillermo Cano-Garcia
Guillermo Cano-Garcia
Abishek WadhwaAbishek Wadhwa
Abishek Wadhwa
KTKaushik Thanki
Kaushik Thanki
Camilla FogedCamilla Foged
Camilla Foged

6 September 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
ACAkash Chakravarty
Akash Chakravarty
TRThomas Rades
Thomas Rades
DCDennis Christensen
Dennis Christensen
HFHenrik Franzyk
Henrik Franzyk
Camilla FogedCamilla Foged
Camilla Foged
Robust, sensitive, and versatile analytical methods are essential for quantification of RNA drug cargos loaded into nanoparticle-based delivery systems. However, simultaneous quantification of multiple RNA cargos co-loaded into nanoparticles remains a challenge. Here, we developed and validated the use of ion-pair reversed-phase high-performance liquid chromatography combined with UV detection (IP-RP-HPLC-UV) for simultaneous quantification of single- and double-stranded RNA cargos. Complete extraction of RNA cargo from the nanoparticle carrier was achieved using a phenol:chloroform:isoamyl alcohol mixture. Separations were performed using either a C18 or a PLRP-S column, eluted with 0.1 M triethylammonium acetate (TEAA) solution as ion-pairing reagent (eluent A), and 0.1 M TEAA containing 25 % (v/v) CH3CN as eluent B. These methods were applied to quantify mRNA and polyinosinic:polycytidylic acid co-loaded into lipid-polymer hybrid nanoparticles, and single-stranded oligodeoxynucleotide donors and Alt-R CRISPR single guide RNAs co-loaded into lipid nanoparticles. The developed methods were sensitive (limit of RNA quantification < 60 ng), linear (R2 > 0.997), and accurate (≈ 100 % recovery of RNA spiked in nanoparticles). Hence, the present study may facilitate convenient quantification of multiple RNA cargos co-loaded into nanoparticle-based delivery systems.

14 January 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
Aneesh ThakurAneesh Thakur
Aneesh Thakur
Abishek WadhwaAbishek Wadhwa
Abishek Wadhwa
KTKaushik Thanki
Kaushik Thanki
HFHenrik Franzyk
Henrik Franzyk
Camilla FogedCamilla Foged
Camilla Foged
RNA interference (RNAi) has an unprecedented potential as a therapeutic strategy for reversibly silencing the expression of any gene. Therapeutic delivery of the RNAi mediator, i.e., small interfering RNA (siRNA), can be used to address diseases characterized by gene overexpression, for example inflammatory conditions like chronic obstructive pulmonary disease (COPD). Macrophages play a key role in COPD pathogenesis and are recruited to the airways and lung parenchyma, where they release proinflammatory cytokines, e.g., tumor necrosis factor-alpha (TNF-α). Hence, targeting TNF-α with siRNA is a promising therapeutic approach for COPD management. However, a safe and effective delivery system is required for delivery of TNF-α siRNA into the cytosol of hard-to-transfect macrophages. The purpose of this study was to optimize the intracellular delivery of TNF-α siRNA to the lipopolysaccharide-activated murine macrophage cell line RAW 264.7 using lipidoid-polymer hybrid nanoparticles (LPNs) composed of the lipid-like transfection agent lipidoid 5 (L5) and the biodegradable polymer poly (D,L-lactide-co-glycolide). Applying a quality-by-design approach, the influence of critical formulation variables, i.e., the L5content and the L5:siRNA ratio (w/w), on critical quality attributes (CQAs) was investigated systematically using risk assessment and design of experiments, followed by delineation of an optimal operating space (OOS). The CQAs were identified based on the quality target product profile and included size, polydispersity index, zeta potential, encapsulation efficiency and loading for achieving efficient and safe TNF-α gene silencing in activated RAW 264.7 cells. Formulations inducing efficient gene silencing and low cytotoxicity were identified, and the optimal formulations displayed L5contents of 15 and 20% (w/w), respectively, and an L5:siRNA weight ratio of 15:1. All tested formulations within the OOS mediated efficient and sequence-specific TNF-α gene silencing in RAW 264.7 cells at TNF-α-siRNA concentrations, which were significantly lower than the concentrations required of non-encapsulated TNF-α-siRNA, highlighting the benefit of the delivery system. The results also demonstrate that increasing the loading of siRNA into the delivery system does not necessarily imply enhanced gene silencing. This opens new avenues for further exploitation of LPNs as a robust platform technology for delivering TNF-α siRNA to macrophages, e.g., in the management of COPD.

9 January 2019 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
KTKaushik Thanki
Kaushik Thanki
SPSimon Papai
Simon Papai
Abhijeet LokrasAbhijeet Lokras
Abhijeet Lokras
FRFabrice Rose
Fabrice Rose
EFEmily Falkenberg
Emily Falkenberg
Camilla FogedCamilla Foged
Camilla Foged